FDA DEVICE FACTS
CellDx-Tissue
Datar Cancer Genetics Private Limited
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The CellDx-Tissue is a qualitative in vitro diagnostic (IVD) test that uses next-generation sequencing of DNA and RNA isolated from formalin-fixed paraffine-embedded (FFPE) tumor tissue from patients previously diagnosed with solid malignant neoplasm to detect tumor gene alterations in a broad multi-gene panel. The test is intended to provide tumor mutation profiling information on somatic mutations, including single nucleotide variants (SNVs), insertions and deletions (indels), one gene amplification, and three fusions. Information provided by the CellDx-Tissue test is intended for use by qualified healthcare professionals in accordance with professional guidelines in oncology. Results from CellDx-Tissue are not intended to be conclusive or prescriptive for the labeled use of any specific therapeutic product. CellDx-Tissue is a single-site assay performed at Datar Cancer Genetics (DCG).
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。